Skip to content

Clinical study for the effect of allopurinol in different doses on the gout flares

Clinical study for the effect of allopurinol in different doses on the gout flares

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900024963
Enrollment
Unknown
Registered
2019-08-05
Start date
2019-08-05
Completion date
Unknown
Last updated
2019-08-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

gout

Interventions

A:The dosage of Allopurinol will increased gradually from 50 mg/d in the first four weeks,100 mg/d in the next four weeks, and to 200 mg/d to the end.
B:Allopurinol 200mg/d + Colchicine 0.5 mg/d.
C:Allopurinol 200mg/d

Sponsors

Anqing Hospital Affiliated to Anhui Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1) All enrolled patients met the 1977 American college of rheumatology (ACR) gout classification criteria and/or the 2015 ACR gout classification criteria; 2) It is developed gout flares at least once in the previous year; 3) Serum uric acid >7.0mg/dl (420umol/L); 4) At least 1 month before entering the study, no uricate-lowering drugs were given; 5) Included in the study with written informed consent.

Exclusion criteria

Exclusion criteria: 1) Aged 1.5 mg/dL (133umol/L); 5) Those with severe comorbid conditions and those whom the researchers judged to be unsuitable candidates for the study.

Design outcomes

Primary

MeasureTime frame
uric acid;

Countries

China

Contacts

Public ContactGuihong Wang

Department of Rheumatology, Anqing Hospital Affiliated to Anhui Medical University

aqfsmy2010@163.com+86 13866449332

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026